We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

174 hedge funds and large institutions have $304M invested in PDL BioPharma, Inc. in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more call options, than puts

Call options by funds: $342K | Put options by funds: $306K

10% more capital invested

Capital invested by funds: $276M → $304M (+$28.2M)

8% less funds holding

Funds holding: 190 → 174 (-16)

18% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 60

33% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 30

Holders
174
Holders Change
-16
Holders Change %
-8.42%
% of All Funds
4.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
49
Reduced
60
Closed
30
Calls
$342K
Puts
$306K
Net Calls
+$36K
Net Calls Change
-$1.12M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$31.7M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$7.29M
3
Citadel Advisors
Citadel Advisors
Florida
+$5.41M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.1M
5
SCP
Seizert Capital Partners
Michigan
+$2.64M

Top Sellers

Rank Fund Capital Flow
1
Robeco Institutional Asset Management
Robeco Institutional Asset Management
Netherlands
-$4.31M
2
JIM
Jupiter Investment Management
United Kingdom
-$2.88M
3
Northern Trust
Northern Trust
Illinois
-$2.5M
4
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
-$2.23M
5
ACPU
Arrowgrass Capital Partners (US)
Delaware
-$2.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
FANJ
151
Financial Architects (New Jersey)
New Jersey
$8K – – –
AG
152
Advisor Group
Arizona
$7K +$555 +251 +9%
First Eagle Investment Management
153
First Eagle Investment Management
New York
$6K – – –
IF
154
Ironwood Financial
Arizona
$3K – – –
CCM
155
Cribstone Capital Management
Maine
$2K – – –
WCBA
156
Weaver C. Barksdale & Associates
Tennessee
$2K – – –
WIM
157
Westside Investment Management
California
$1.06K – – –
DA
158
Denali Advisors
California
$1K – – –
IA
159
IFP Advisors
Florida
$1K – – –
LWCFA
160
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$1K – – –
SEI Investments
161
SEI Investments
Pennsylvania
$1K – – –
SPIA
162
Steward Partners Investment Advisory
New York
$1K – – –
US Bancorp
163
US Bancorp
Minnesota
$1K – – –
WA
164
Winfield Associates
Ohio
$1K – – –
IWM
165
IHT Wealth Management
Illinois
$1K +$940 +425 New
WAM
166
Wealthspire Advisors (Maryland)
Maryland
$1K +$1.42K +642 New
Walleye Trading
167
Walleye Trading
New York
$38 +$32.1K +14,500 +630%
JIM
168
Jupiter Investment Management
United Kingdom
– -$2.88M -1,360,735 Closed
ACPU
169
Arrowgrass Capital Partners (US)
Delaware
– -$2.17M -1,022,951 Closed
PWAM
170
Park West Asset Management
California
– -$848K -400,000 Closed
CI
171
Cigna Investments
Connecticut
– -$554K -261,533 Closed
FQ
172
First Quadrant
California
– -$551K -259,833 Closed
EGA
173
Eagle Global Advisors
Texas
– -$435K -205,190 Closed
SCM
174
Sterling Capital Management
North Carolina
– -$434K -204,916 Closed
DCM
175
Dynamic Capital Management
Jersey
– -$314K -147,992 Closed
4 5 6
7
8

PDLI Hedge Fund Activity: Q1 2017 in Review

174 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2017, worth a combined $304M — up 10% from $276M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PDLI and 20 opened new positions — a net loss of 10 holders — while 60 trimmed existing stakes and 49 added.

The largest buyer was BlackRock, adding an estimated $31.7M. The largest seller was Robeco Institutional Asset Management, cutting an estimated $4.31M.

  • 174 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2017, down from 190 in Q4 2016.
  • Funds reported $304M of PDL BioPharma, Inc. stock for Q1 2017, up 10% quarter-over-quarter.
  • 20 funds opened new PDL BioPharma, Inc. positions in Q1 2017 and 30 closed out, a net change of -10 holders.
  • The largest PDL BioPharma, Inc. buyer in Q1 2017 was BlackRock, an estimated $31.7M added.
  • The largest PDL BioPharma, Inc. seller in Q1 2017 was Robeco Institutional Asset Management, an estimated $4.31M sold.

Based on aggregated 13F filings for Q1 2017.